{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:59:25Z","timestamp":1790402365612,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:00:00Z","timestamp":1627948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Semnan University of Medical Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Family with sequence similarity 19 (chemokine (C-C motif)-like) member A5 (FAM19A5) is a newly identified adipokine. There is a limited number of studies linking FAM19A5 to metabolic disorders. In the current study, we aimed to explore if FAM19A5 is associated with nonalcoholic fatty liver disease (NAFLD). We also sought to determine the possibility of FAM19A5 association with subclinical atherosclerosis in NAFLD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 69 subjects including 37 NAFLD and 32 control subjects were included in this cross-sectional study. Plasma concentration of FAM19A5 was measured with the ELISA method. Carotid artery intima-media thickness (cIMT) was assessed by the ultrasonography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Plasma concentration of FAM19A5 in patients with NAFLD was significantly lower in NAFLD patients than controls. Moreover, we observed significant negative correlations between plasma level of FAM19A5 and body mass index (BMI), visceral fat, alanine amino transferase (ALT), aspartate amino transferase (AST), liver stiffness (LS), and cIMT. Following stepwise multiple linear regression analysis, ALT and cIMT were the only determinants of FAM19A5 level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first report to describe association of circulating FAM19A5 levels with NAFLD. Our findings provide further evidence showing relation of FAM19A5 with the risk of atherosclerosis. However, more studies are necessary to unravel the contribution of lower FAM19A5 levels to the NAFLD pathogenesis and the higher risk of atherosclerosis in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-021-00820-8","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T01:33:08Z","timestamp":1628818388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Fatemeh Ali","family":"Yari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Shabani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negar","family":"Sarmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Poustchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Reza","family":"Bandegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,3]]},"reference":[{"key":"820_CR1","doi-asserted-by":"crossref","unstructured":"Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines. 2019;6(1).","DOI":"10.3390\/medicines6010041"},{"issue":"1","key":"820_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology."},{"key":"820_CR3","doi-asserted-by":"crossref","unstructured":"Ragino YI, Stakhneva EM, Polonskaya YV, Kashtanova EV. The role of secretory activity molecules of visceral adipocytes in abdominal obesity in the development of cardiovascular disease: a review. Biomolecules. 2020;10(3).","DOI":"10.3390\/biom10030374"},{"issue":"3","key":"820_CR4","doi-asserted-by":"publisher","first-page":"e0118650","DOI":"10.1371\/journal.pone.0118650","volume":"10","author":"P Shabani","year":"2015","unstructured":"Shabani P, Naeimi Khaledi H, Beigy M, Emamgholipour S, Parvaz E, Poustchi H, et al. Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance? PLoS One. 2015;10(3):e0118650. https:\/\/doi.org\/10.1371\/journal.pone.0118650.","journal-title":"PLoS One"},{"issue":"12","key":"820_CR5","doi-asserted-by":"publisher","first-page":"e0168082","DOI":"10.1371\/journal.pone.0168082","volume":"11","author":"M Shanaki","year":"2016","unstructured":"Shanaki M, Fadaei R, Moradi N, Emamgholipour S, Poustchi H. The circulating CTRP13 in type 2 diabetes and non-alcoholic fatty liver patients. PLoS One. 2016;11(12):e0168082. https:\/\/doi.org\/10.1371\/journal.pone.0168082.","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"820_CR6","doi-asserted-by":"publisher","first-page":"S467","DOI":"10.1016\/j.dsx.2017.03.037","volume":"11","author":"M Shanaki","year":"2017","unstructured":"Shanaki M, Moradi N, Emamgholipour S, Fadaei R, Poustchi H. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes Metab Syndr. 2017;11(Suppl 1):S467\u2013S72. https:\/\/doi.org\/10.1016\/j.dsx.2017.03.037.","journal-title":"Diabetes Metab Syndr"},{"issue":"1","key":"820_CR7","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13098-015-0099-z","volume":"7","author":"S Emamgholipour","year":"2015","unstructured":"Emamgholipour S, Moradi N, Beigy M, Shabani P, Fadaei R, Poustchi H, et al. The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study. Diabetol Metab Syndr. 2015;7(1):108. https:\/\/doi.org\/10.1186\/s13098-015-0099-z.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"820_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.117.032398","volume":"138","author":"Y Wang","year":"2018","unstructured":"Wang Y, Chen D, Zhang Y, Wang P, Zheng C, Zhang S, et al. Novel Adipokine, FAM19A5, inhibits Neointima formation after injury through Sphingosine-1-phosphate receptor 2. Circulation. 2018;138(1):48\u201363. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032398.","journal-title":"Circulation."},{"issue":"6","key":"820_CR9","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/1479164119860746","volume":"16","author":"YB Lee","year":"2019","unstructured":"Lee YB, Hwang HJ, Kim JA, Hwang SY, Roh E, Hong SH, et al. Association of serum FAM19A5 with metabolic and vascular risk factors in human subjects with or without type 2 diabetes. Diab Vasc Dis Res. 2019;16(6):530\u20138. https:\/\/doi.org\/10.1177\/1479164119860746.","journal-title":"Diab Vasc Dis Res"},{"issue":"2","key":"820_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.atherosclerosis.2015.02.011","volume":"239","author":"M Al Rifai","year":"2015","unstructured":"Al Rifai M, Silverman MG, Nasir K, Budoff MJ, Blankstein R, Szklo M, et al. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2015;239(2):629\u201333. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.02.011.","journal-title":"Atherosclerosis."},{"issue":"1","key":"820_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12872-018-0877-2","volume":"18","author":"J Zheng","year":"2018","unstructured":"Zheng J, Zhou Y, Zhang K, Qi Y, An S, Wang S, et al. Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old. BMC Cardiovasc Disord. 2018;18(1):147. https:\/\/doi.org\/10.1186\/s12872-018-0877-2.","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"820_CR12","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138\u201353. https:\/\/doi.org\/10.1136\/gutjnl-2017-313884.","journal-title":"Gut."},{"issue":"12","key":"820_CR13","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.jacc.2019.08.012","volume":"74","author":"A Ahmadi","year":"2019","unstructured":"Ahmadi A, Argulian E, Leipsic J, Newby DE, Narula J. From subclinical atherosclerosis to plaque progression and acute coronary events: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(12):1608\u201317. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.012.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl E","key":"820_CR14","doi-asserted-by":"publisher","first-page":"E87","DOI":"10.1093\/eurheartj\/suaa068","volume":"22","author":"L Gatto","year":"2020","unstructured":"Gatto L, Prati F. Subclinical atherosclerosis: how and when to treat it? Eur Heart J Suppl. 2020;22(Suppl E):E87\u2013e90.","journal-title":"Eur Heart J Suppl"},{"issue":"1","key":"820_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s12889-018-5263-6","volume":"18","author":"SS Singh","year":"2018","unstructured":"Singh SS, Pilkerton CS, Shrader CD Jr, Frisbee SJ. Subclinical atherosclerosis, cardiovascular health, and disease risk: is there a case for the cardiovascular health index in the primary prevention population? BMC Public Health. 2018;18(1):429. https:\/\/doi.org\/10.1186\/s12889-018-5263-6.","journal-title":"BMC Public Health"},{"issue":"2","key":"820_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4291\/wjgp.v8.i2.51","volume":"8","author":"R Patil","year":"2017","unstructured":"Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol. 2017;8(2):51\u20138. https:\/\/doi.org\/10.4291\/wjgp.v8.i2.51.","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"1","key":"820_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13813455.2018.1429475","volume":"125","author":"R Fadaei","year":"2019","unstructured":"Fadaei R, Meshkani R, Poustchi H, Fallah S, Moradi N, Panahi G, et al. Association of carotid intima media thickness with atherogenic index of plasma, apo B\/apo A-I ratio and paraoxonase activity in patients with non-alcoholic fatty liver disease. Arch Physiol Biochem. 2019;125(1):19\u201324. https:\/\/doi.org\/10.1080\/13813455.2018.1429475.","journal-title":"Arch Physiol Biochem"},{"issue":"5","key":"820_CR18","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/hep.25555","volume":"55","author":"M Kozakova","year":"2012","unstructured":"Kozakova M, Palombo C, Eng MP, Dekker J, Flyvbjerg A, Mitrakou A, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology. 2012;55(5):1406\u201315. https:\/\/doi.org\/10.1002\/hep.25555.","journal-title":"Hepatology."},{"issue":"10","key":"820_CR19","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.2337\/diacare.27.10.2498","volume":"27","author":"G Targher","year":"2004","unstructured":"Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care. 2004;27(10):2498\u2013500. https:\/\/doi.org\/10.2337\/diacare.27.10.2498.","journal-title":"Diabetes Care"},{"issue":"12","key":"820_CR20","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.3748\/wjg.v11.i12.1848","volume":"11","author":"H Volzke","year":"2005","unstructured":"Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol. 2005;11(12):1848\u201353. https:\/\/doi.org\/10.3748\/wjg.v11.i12.1848.","journal-title":"World J Gastroenterol"},{"key":"820_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1741-7015-9-25","volume":"9","author":"N Maenhaut","year":"2011","unstructured":"Maenhaut N, Van de Voorde J. Regulation of vascular tone by adipocytes. BMC Med. 2011;9:25.","journal-title":"BMC Med"},{"key":"820_CR22","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.bbi.2020.03.021","volume":"87","author":"KM Han","year":"2020","unstructured":"Han KM, Tae WS, Kim A, Kang Y, Kang W, Kang J, et al. Serum FAM19A5 levels: A novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder. Brain Behav Immun. 2020;87:852\u20139. https:\/\/doi.org\/10.1016\/j.bbi.2020.03.021.","journal-title":"Brain Behav Immun"},{"key":"820_CR23","doi-asserted-by":"publisher","unstructured":"Huang S, Zheng C, Xie G, Song Z, Wang P, Bai Y, et al. FAM19A5\/TAFA5, a novel neurokine, plays a crucial role in depressive-like and spatial memory-related behaviors in mice. Mol Psychiatry. 2020. https:\/\/doi.org\/10.1038\/s41380-020-0720-x.","DOI":"10.1038\/s41380-020-0720-x"},{"issue":"4","key":"820_CR24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.bbrc.2019.12.119","volume":"523","author":"D Kang","year":"2020","unstructured":"Kang D, Kim HR, Kim KK, Kim DH, Jeong B, Jin S, et al. Brain-specific chemokine FAM19A5 induces hypothalamic inflammation. Biochem Biophys Res Commun. 2020;523(4):829\u201334. https:\/\/doi.org\/10.1016\/j.bbrc.2019.12.119.","journal-title":"Biochem Biophys Res Commun"},{"key":"820_CR25","doi-asserted-by":"crossref","unstructured":"Lee HL, Seok HY, Ryu HW, Cho EB, Kim BC, Kim BJ, et al. Serum FAM19A5 in neuromyelitis optica spectrum disorders: can it be a new biomarker representing clinical status? Mult Scler. 2019;1352458519885489.","DOI":"10.1177\/1352458519885489"},{"issue":"1","key":"820_CR26","doi-asserted-by":"publisher","first-page":"15575","DOI":"10.1038\/s41598-017-15586-0","volume":"7","author":"MY Park","year":"2017","unstructured":"Park MY, Kim HS, Lee M, Park B, Lee HY, Cho EB, et al. FAM19A5, a brain-specific chemokine, inhibits RANKL-induced osteoclast formation through formyl peptide receptor 2. Sci Rep. 2017;7(1):15575. https:\/\/doi.org\/10.1038\/s41598-017-15586-0.","journal-title":"Sci Rep"},{"issue":"8","key":"820_CR27","first-page":"515","volume":"18","author":"S Merat","year":"2015","unstructured":"Merat S, Poustchi H, Hemming K, Jafari E, Radmard AR, Nateghi A, et al. PolyPill for prevention of cardiovascular disease in an urban Iranian population with special focus on nonalcoholic Steatohepatitis: a pragmatic randomized controlled trial within a cohort (PolyIran - liver) - study protocol. Arch Iran Med. 2015;18(8):515\u201323.","journal-title":"Arch Iran Med"},{"issue":"6","key":"820_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/15513815.2019.1604921","volume":"38","author":"C Inan","year":"2019","unstructured":"Inan C, Sayin NC, Gurkan H, Atli E, Gursoy Erzincan S, Uzun I, et al. Schizencephaly accompanied by occipital encephalocele and deletion of chromosome 22q13.32: a case report. Fetal Pediatr Pathol. 2019;38(6):496\u2013502. https:\/\/doi.org\/10.1080\/15513815.2019.1604921.","journal-title":"Fetal Pediatr Pathol"},{"key":"820_CR29","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3389\/fnins.2019.00917","volume":"13","author":"A Shahapal","year":"2019","unstructured":"Shahapal A, Cho EB, Yong HJ, Jeong I, Kwak H, Lee JK, et al. FAM19A5 expression during embryogenesis and in the adult traumatic brain of FAM19A5-LacZ Knock-in mice. Front Neurosci. 2019;13:917. https:\/\/doi.org\/10.3389\/fnins.2019.00917.","journal-title":"Front Neurosci"},{"issue":"22","key":"820_CR30","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1242\/dev.153700","volume":"144","author":"X Pan","year":"2017","unstructured":"Pan X, Karner CM, Carroll TJ. Myc cooperates with beta-catenin to drive gene expression in nephron progenitor cells. Development. 2017;144(22):4173\u201382. https:\/\/doi.org\/10.1242\/dev.153700.","journal-title":"Development."},{"key":"820_CR31","doi-asserted-by":"publisher","first-page":"578966","DOI":"10.3389\/fphys.2020.578966","volume":"11","author":"L Recinella","year":"2020","unstructured":"Recinella L, Orlando G, Ferrante C, Chiavaroli A, Brunetti L, Leone S. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Front Physiol. 2020;11:578966. https:\/\/doi.org\/10.3389\/fphys.2020.578966.","journal-title":"Front Physiol"},{"issue":"6","key":"820_CR32","doi-asserted-by":"publisher","first-page":"e66515","DOI":"10.1371\/journal.pone.0066515","volume":"8","author":"F Tourniaire","year":"2013","unstructured":"Tourniaire F, Romier-Crouzet B, Lee JH, Marcotorchino J, Gouranton E, Salles J, et al. Chemokine expression in inflamed adipose tissue is mainly mediated by NF-\u03baB. PLoS One. 2013;8(6):e66515. https:\/\/doi.org\/10.1371\/journal.pone.0066515.","journal-title":"PLoS One"},{"key":"820_CR33","doi-asserted-by":"publisher","unstructured":"Ebrahimi R, Shanaki M, Mohassel Azadi S, Bahiraee A, Radmard AR, Poustchi H, et al. Low level of adiponectin predicts the development of nonalcoholic fatty liver disease: is it irrespective to visceral adiposity index, visceral adipose tissue thickness and other obesity indices? Arch Physiol Biochem. 2019:1\u20138. https:\/\/doi.org\/10.1080\/13813455.2019.1661496.","DOI":"10.1080\/13813455.2019.1661496"},{"issue":"9","key":"820_CR34","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.metabol.2012.02.005","volume":"61","author":"UI Khan","year":"2012","unstructured":"Khan UI, Wang D, Sowers MR, Mancuso P, Everson-Rose SA, Scherer PE, et al. Race-ethnic differences in adipokine levels: the study of Women's health across the nation (SWAN). Metabolism. 2012;61(9):1261\u20139. https:\/\/doi.org\/10.1016\/j.metabol.2012.02.005.","journal-title":"Metabolism."},{"issue":"1","key":"820_CR35","doi-asserted-by":"publisher","first-page":"9993","DOI":"10.1038\/s41598-020-66330-0","volume":"10","author":"H Bonakdari","year":"2020","unstructured":"Bonakdari H, Tardif G, Abram F, Pelletier JP, Martel-Pelletier J. Serum adipokines\/related inflammatory factors and ratios as predictors of infrapatellar fat pad volume in osteoarthritis: applying comprehensive machine learning approaches. Sci Rep. 2020;10(1):9993. https:\/\/doi.org\/10.1038\/s41598-020-66330-0.","journal-title":"Sci Rep"},{"issue":"3","key":"820_CR36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1530\/EJE-12-0688","volume":"168","author":"T Eglit","year":"2013","unstructured":"Eglit T, Lember M, Ringmets I, Rajasalu T. Gender differences in serum high-molecular-weight adiponectin levels in metabolic syndrome. Eur J Endocrinol. 2013;168(3):385\u201391. https:\/\/doi.org\/10.1530\/EJE-12-0688.","journal-title":"Eur J Endocrinol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00820-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00820-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00820-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T04:01:28Z","timestamp":1673064088000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00820-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,3]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["820"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00820-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-42124\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,3]]},"assertion":[{"value":"13 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the medical ethics committee of Semnan University of Medical Sciences, and the written informed consent was obtained from all participants according to the guidelines of Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}